Jeil Pharmaceutical Co Ltd (KO:271980) — Market Cap & Net Worth
Market Cap & Net Worth: Jeil Pharmaceutical Co Ltd (271980)
Jeil Pharmaceutical Co Ltd (KO:271980) has a market capitalization of $138.25 Million (₩204.00 Billion) as of May 4, 2026. Listed on the KO stock exchange, this Korea-based company holds position #17939 globally and #875 in its home market, demonstrating a 1.01% increase in market value over the past year.
Market capitalization, also known as net worth in stock markets, is calculated by multiplying Jeil Pharmaceutical Co Ltd's stock price ₩14000.00 by its total outstanding shares 14571517 (14.57 Million). Analyse Jeil Pharmaceutical Co Ltd cash conversion from operations to see how efficiently the company converts income to cash.
Jeil Pharmaceutical Co Ltd Market Cap History: 2017 to 2026
Jeil Pharmaceutical Co Ltd's market capitalization history from 2017 to 2026. Data shows change from $432.87 Million to $138.25 Million (-12.74% CAGR).
Jeil Pharmaceutical Co Ltd Market Cap to Earnings & Revenue Ratios Timeline
This chart shows how Jeil Pharmaceutical Co Ltd's valuation ratios have evolved. The Price to Sales (P/S) ratio compares market cap to revenue, while the Price to Earnings (P/E) ratio compares market cap to net income. Lower values may indicate a more undervalued company relative to its financial performance.
Latest Price to Sales (P/S) Ratio
0.00x
Jeil Pharmaceutical Co Ltd's market cap is 0.00 times its annual revenue
Latest Price to Earnings (P/E) Ratio
N/A
P/E ratio not applicable due to negative or zero earnings
What These Ratios Tell Investors:
- Price to Sales (P/S) Ratio: Shows how much investors are paying for each dollar of the company's sales. Lower P/S ratios may indicate undervaluation.
- Price to Earnings (P/E) Ratio: Shows how much investors are paying for each dollar of the company's earnings. This is one of the most common valuation metrics.
- Trends in these ratios over time can indicate changing investor sentiment about the company's future growth prospects.
- Industry comparison provides context for whether the company is valued higher or lower than peers.
| Year | Market Cap (USD) | Revenue (USD) | Net Income (USD) | P/S Ratio | P/E Ratio |
|---|---|---|---|---|---|
| 2017 | $432.87 Million | $371.59 Billion | $1.07 Billion | 0.00x | 0.41x |
| 2018 | $455.41 Million | $627.07 Billion | $1.89 Billion | 0.00x | 0.24x |
| 2019 | $354.46 Million | $671.41 Billion | -$10.58 Billion | 0.00x | N/A |
| 2020 | $613.68 Million | $691.32 Billion | $6.92 Billion | 0.00x | 0.09x |
| 2021 | $332.45 Million | $700.69 Billion | -$12.47 Billion | 0.00x | N/A |
| 2022 | $206.76 Million | $722.23 Billion | -$13.09 Billion | 0.00x | N/A |
| 2023 | $168.86 Million | $726.39 Billion | $5.00 Billion | 0.00x | 0.03x |
| 2024 | $112.57 Million | $704.54 Billion | -$29.97 Billion | 0.00x | N/A |
Competitor Companies of 271980 by Market Capitalization
Companies near Jeil Pharmaceutical Co Ltd in the global market cap rankings as of May 4, 2026.
Key companies related to Jeil Pharmaceutical Co Ltd by market ranking:
- Takeda Pharmaceutical Co Ltd ADR (NYSE:TAK): Ranked #499 globally with a market cap of $52.60 Billion USD.
- Zoetis Inc (NYSE:ZTS): Ranked #525 globally with a market cap of $50.31 Billion USD.
- Jiangsu Hengrui Medicine Co Ltd (SHG:600276): Ranked #526 globally with a market cap of $50.29 Billion USD ( CN¥343.70 Billion CNY).
- GALDERMA GROUP AG (NYSE:GALDY): Ranked #572 globally with a market cap of $45.88 Billion USD.
| Rank | Company | Symbol | Market Cap | Price |
|---|---|---|---|---|
| #499 | Takeda Pharmaceutical Co Ltd ADR | NYSE:TAK | $52.60 Billion | $16.65 |
| #525 | Zoetis Inc | NYSE:ZTS | $50.31 Billion | $114.16 |
| #526 | Jiangsu Hengrui Medicine Co Ltd | SHG:600276 | $50.29 Billion | CN¥53.88 |
| #572 | GALDERMA GROUP AG | NYSE:GALDY | $45.88 Billion | $42.09 |
Jeil Pharmaceutical Co Ltd Historical Marketcap From 2017 to 2026
Between 2017 and today, Jeil Pharmaceutical Co Ltd's market cap moved from $432.87 Million to $ 138.25 Million, with a yearly change of -12.74%.
| Year | Market Cap | Change (%) |
|---|---|---|
| 2026 | ₩138.25 Million | -7.59% |
| 2025 | ₩149.60 Million | +32.89% |
| 2024 | ₩112.57 Million | -33.33% |
| 2023 | ₩168.86 Million | -18.33% |
| 2022 | ₩206.76 Million | -37.81% |
| 2021 | ₩332.45 Million | -45.83% |
| 2020 | ₩613.68 Million | +73.13% |
| 2019 | ₩354.46 Million | -22.17% |
| 2018 | ₩455.41 Million | +5.21% |
| 2017 | ₩432.87 Million | -- |
End of Day Market Cap According to Different Sources
On May 3rd, 2026 the market cap of Jeil Pharmaceutical Co Ltd was reported to be:
| Source | Market Cap |
|---|---|
| Yahoo Finance | $138.25 Million USD |
| MoneyControl | $138.25 Million USD |
| MarketWatch | $138.25 Million USD |
| marketcap.company | $138.25 Million USD |
| Reuters | $138.25 Million USD |
Market cap values may vary slightly between sources due to differences in calculation methods, timing, and data refresh rates.
About Jeil Pharmaceutical Co Ltd
Jeil Pharmaceutical Co.,Ltd develops and supplies pharmaceutical products primarily in South Korea and internationally. It provides products in the areas of antibiotic, gastrointestinal, cardiovascular, neuropsychiatry, oncology, endocrinology, urology, antiviral, and antihistamine. The company exports its products. Jeil Pharmaceutical Co.,Ltd was founded in 1959 and is headquartered in Seoul, So… Read more